Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib in Advanced ER+/PR+ or Her2+ Breast Cancer
NCT00371345Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2006
- Primary completion
- Mar 2009
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 7
01
Overview
A Phase 2 trial of dasatinib in breast cancer, sponsored by Bristol Myers Squibb. Started Dec 2006; status: completed.
02
Drugs
dasatinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00371345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00371345.